Industry committee  We've already taken steps to accommodate for that. With the capacity at the Northern RNA facility in Calgary partnered with the capacity of the Emergent BioSolutions facility in Manitoba, we have the ability to produce over 120 million doses of vaccine.

Industry committee  No.

Industry committee  No.

Industry committee  That's a question for the federal government.

Industry committee  Quite frankly, I already have the discussions going on with the provinces. We're now filling orders. I would welcome support from the federal government and the NRC as we advance the clinical trial forward.

Industry committee  We're not looking for any exceptions. We want to make sure this is done properly.

Industry committee  I don't believe Health Canada functions that way. Our experiences with the bureaucratic functions of the federal government—NGen, NRC, Health Canada—have all been fantastic to date. We have no reason to believe that would not continue on a go-forward basis.

Industry committee  If the question is whether we have the production to make all the different vaccine technologies that are being pursued across the entire platform, the answer is no. We don't. We have production in Canada that's committed to other essential vaccines that still need to be produced

Industry committee  Messenger RNA is the most effective vaccine technology on the planet. In the worldwide race for a COVID vaccine, messenger RNA was the fastest by months, and it was the most effective, at 95% efficacy. It will be the fastest to respond to the variants that are emerging now. It is